FDA approves AbbVie’s mavyret as first and only treatment for acute hepatitis C
Now approved for both acute and chronic HCV in adults and children aged 3 and above
Now approved for both acute and chronic HCV in adults and children aged 3 and above
The company received 1 (One) observation in the Form-483
Revvity launches its first set of IVD Mimix reference standards, providing diagnostic labs with trusted quality controls for optimizing tests and monitoring workflows
Pivotal results from the Phase 3 Breakwater trial showed 51% risk reduction in death compared to standard-of-care treatment
The decision to withdraw the BLA is based on topline overall survival (OS) results from the confirmatory HERTHENA-Lung02 Phase 3 trial where OS did not meet statistical significance
This global affiliation marks a critical step in the company’s mission to create long-term value through ethical practices, scientific innovation, and inclusive healthcare delivery
The CEP certification for Metformin Hydrochloride aligns with the company's strategy to penetrate stringently regulated markets
IGI recently completed the dose-escalation portion of its Phase 1 clinical study in patients with heavily pretreated multiple myeloma
The Simplera Sync is a disposable, all-in-one sensor that requires no fingersticks with SmartGuard
Subscribe To Our Newsletter & Stay Updated